|
Volume 17, Issue 5 (September 2015) 17, 839–844; doi: 10.4103/1008-682X.148138
The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy
Gui-Ming Zhang1, 2,*, Yao Zhu1,*, Da-Hai Dong3, Cheng-Tao Han1, 2, Cheng-Yuan Gu1, Wei-Jie Gu1, 2, Xiao-Jian Qin1, Li-Jiang Sun3, Ding-Wei Ye1, 2
1 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3 Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China
*These authors contributed equally to this work.
Correspondence: Dr. LJ Sun (slijiang999@126.com) or Dr. DW Ye (dwyeli@163.com)
2015-1-16
| Abstract |
|
The global incidence of metabolic syndrome (MetS) is dramatically increasing. Considerable interest has been devoted to the relationship between MetS and prostate cancer (PCa) risk. However, few studies have examined the association between MetS and PCa progression. This retrospective study consisted of 1016 patients with PCa who received radical prostatectomy. The association between MetS and pathological features was evaluated using logistic regression analysis. Compared with patients without MetS, those with MetS indicated an increased risk of prostatectomy Gleason score (GS) ≥8 (odds ratio [OR] =1.670, 95% confidence interval (CI) 1.096-2.545, P= 0.017), and a 1.5-fold increased risk of pT3-4 disease (OR = 1.583, 95% CI 1.106-2.266, P= 0.012). The presence of MetS was an independent predictor of lymph node involvement (OR = 1.751, 95% CI 1.038-2.955, P= 0.036). Furthermore, as the number of MetS components accumulated, the risk of a GS ≥ 8 increased. The present study indicates a significant association between MetS and advanced PCa. The results need to be evaluated in large-scale prospective cohorts.
Full Text |
PDF |
中文摘要 |
|
| |
| Browse: 1670 |
|
